Mats Karlsson
Uppsala Universitet
H-index: 80
Europe-Sweden
Top articles of Mats Karlsson
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Characterization of anti-drug antibody dynamics using a bivariate mixed hidden-markov model by nonlinear-mixed effects approach | Journal of Pharmacokinetics and Pharmacodynamics | Ari Brekkan Rocío Lledo-Garcia Brigitte Lacroix Siv Jönsson Mats O Karlsson | 2024/2 |
Item response theory analysis of daytime sleepiness as a symptom of obstructive sleep apnea | CPT: Pharmacometrics & Systems Pharmacology | Gustaf J Wellhagen Mats O Karlsson Maria C Kjellsson Dirk Garmann Astrid Bröker | 2024/3/12 |
Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia | Leukemia | Merete Dam Maddalena Centanni Lena E Friberg Daniel Centanni Mats O Karlsson | 2024/1/29 |
Properties of the full random‐effect modeling approach with missing covariate data | Statistics in Medicine | Joakim Nyberg E Niclas Jonsson Mats O Karlsson Jonas Häggström | 2024/2/28 |
Assessment of non-linear mixed effects model-based approaches to test for drug effect using simulated data: type I error and power properties | bioRxiv | Estelle Chasseloup Adrien Tessier Mats O Karlsson | 2024 |
Training the next generation of pharmacometric modelers: a multisector perspective (vol 51, pg 5, 2024) | Journal of pharmacokinetics and pharmacodynamics | Peter L Bonate Jeffrey S Barrett Sihem Ait-Oudhia Richard Brundage Brian Corrigan | 2024/2 |
Extension of individual model averaging assessments to unbalanced designs and dose-response | bioRxiv | Estelle Chasseloup Xinyi Li Mats O Karlsson | 2024 |
Comparison of Two Methods for Determining Item Characteristic Functions and Latent Variable Time-Course for Pharmacometric Item Response Models | The AAPS Journal | Leticia Arrington Mats O Karlsson | 2024/2 |
Covariate modeling in pharmacometrics: General points for consideration | Kinjal Sanghavi Jakob Ribbing James A Rogers Mariam A Ahmed Mats O Karlsson | 2024/4/2 | |
Model-Informed Precision Dosing to Reduce Vincristine-Induced Peripheral Neuropathy in Pediatric Patients: A Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis | Clinical Pharmacokinetics | Maddalena Centanni Mirjam E van de Velde Aniek Uittenboogaard Gertjan JL Kaspers Mats O Karlsson | 2024/2 |
Predicting the Long‐Term Effects of Therapeutic Neutralization of Oncostatin M on Human Hematopoiesis | Clinical Pharmacology & Therapeutics | Anders Thorsted Chiara Zecchin Alienor Berges Mats O Karlsson Lena E Friberg | 2024/3/19 |
Assessment of ibrutinib scheduling on leukocyte, lymph node size and blood pressure dynamics in chronic lymphocytic leukemia through pharmacokinetic‐pharmacodynamic models | CPT: Pharmacometrics & Systems Pharmacology | Eman IK Ibrahim Mats O Karlsson Lena E Friberg | 2023/9 |
Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children | Maddalena Centanni David Elhad Omar Zaher Mats O Karlsson Lena E Friberg | 2023/12/8 | |
Association between sports participation, factor VIII levels and bleeding in hemophilia A | Thrombosis and haemostasis | Laura H Bukkems Olav Versloot Marjon H Cnossen Siv Jönsson Mats O Karlsson | 2023/3 |
Population pharmacokinetics of levodopa and carbidopa following subcutaneous infusion | Parkinsonism & Related Disorders | T Birnberg L Adar G Smania M Bjornsson N Jonsson | 2023/8/1 |
Evaluation of the effect of erenumab on migraine‐specific questionnaire in patients with chronic and episodic migraine | CPT: Pharmacometrics & Systems Pharmacology | Po‐Wei Chen Mats O Karlsson Sebastian Ueckert Ari Pritchard‐Bell Cheng‐Pang Hsu | 2023/12 |
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study | The Lancet | Jesse J Swen Cathelijne H van der Wouden Lisanne EN Manson Heshu Abdullah-Koolmees Kathrin Blagec | 2023/2/4 |
Joint longitudinal model-based meta-analysis of FEV1 and exacerbation rate in randomized COPD trials | Journal of Pharmacokinetics and Pharmacodynamics | Carolina Llanos-Paez Claire Ambery Shuying Yang Misba Beerahee Elodie L Plan | 2023/8 |
How to analyze continuous and discrete repeated measures in small-sample cross-over trials? | Biometrics | Johan Verbeeck Martin Geroldinger Konstantin Thiel Andrew Craig Hooker Sebastian Ueckert | 2023/12 |
Comparison of Seven Non-Linear Mixed Effect Model-Based Approaches to Test for Treatment Effect | Pharmaceutics | Estelle Chasseloup Mats O Karlsson | 2023/1/30 |
Co-Authors
